The Centers for Medicare and Medicaid Services (CMS) issued final payment determinations for Progentec Diagnostics’ proprietary tests, the aiSLE DX Flare Risk Index (FRI) and aiSLE DX Disease Activity Index (DAI) biomarker tests. Starting on January 1, 2025, Medicare claims for these tests, billed under PLA codes 0446U (FRI) and 0447U (DAI) will be paid at a rate of $840.65, provided the tests are covered by Medicare.
The aiSLE™ DX FRI is an advanced blood test designed to predict the risk of a systemic lupus erythematosus (SLE) flare within the next 12 weeks, while the aiSLE DX DAI measures current disease activity, helping healthcare professionals assess treatment effectiveness. . Physicians can order these tests through Mayo Clinic Laboratories.
Continue to follow the Lupus Foundation of America for updates on the latest lupus news. Learn more about lab tests for lupus.
This post was originally published on this site